Antibody drug discovery and development company Sanyou Biopharmaceuticals said on Tuesday that it was recognised with the '2025 Best Customer Satisfaction CRO Award' at the 7th China Bio Innovation Expo awards ceremony, which took place in Suzhou, China on 1 August.
The award recognised the company's deep expertise and outstanding performance in the field of preclinical research for new drug development.
According to Sanyou Bio, this award reflects the industry's high regard for the company's overall capabilities and also serves as strong validation of its commitment to driving innovation in biopharmaceutical R&D.
The company stated: "Winning the '2025 Best Customer Satisfaction CRO Award' is a testament to Sanyou Bio's past achievements and a powerful motivation for future growth. We sincerely thank our peers and partners across the industry for their continued trust and support. Sanyou Bio will remain true to its mission and continue forging ahead, striving for new milestones on the path of biopharmaceutical innovation."
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA